within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BH05_Linagliptin;

model Linagliptin
  extends Pharmacolibrary.Drugs.ATC.A.A10BH05;

  annotation (Documentation(
info       = "<html><body><table><tr><td>name:</td><td>Linagliptin</td></tr><tr><td>ATC code:</td><td>A10BH05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used for the treatment of type 2 diabetes mellitus. It helps to improve glycaemic control by increasing incretin levels, thereby stimulating insulin release and decreasing glucagon secretion. Linagliptin is approved and widely used today for the management of type 2 diabetes.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported for healthy adult subjects (both males and females), after single oral administration.</p><h4>References</h4><ol><li><p>Ceriello, A, &amp; Inagaki, N (2017). Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations. <i>Journal of diabetes investigation</i> 8(1) 19–28. DOI:<a href=\"https://doi.org/10.1111/jdi.12528\">10.1111/jdi.12528</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27180612/\">https://pubmed.ncbi.nlm.nih.gov/27180612</a></p></li><li><p>Forst, T, &amp; Pfützner, A (2012). Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes. <i>Expert opinion on pharmacotherapy</i> 13(1) 101–110. DOI:<a href=\"https://doi.org/10.1517/14656566.2012.642863\">10.1517/14656566.2012.642863</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22149370/\">https://pubmed.ncbi.nlm.nih.gov/22149370</a></p></li><li><p>Retlich, S, et al., &amp; Graefe-Mody, U (2010). Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects. <i>Clinical pharmacokinetics</i> 49(12) 829–840. DOI:<a href=\"https://doi.org/10.2165/11536620-000000000-00000\">10.2165/11536620-000000000-00000</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21053992/\">https://pubmed.ncbi.nlm.nih.gov/21053992</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Linagliptin;
